|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
inhibits cellular proliferation and ACTH production in corticotroph tumor cells through a novel janus kinases–signal transducer and activator of transcription 1/nuclear factor-kappa B inhibitory signaling pathway
1 Department of Neuroendocrinology2 , Department of Molecular Neurogenetics3 Department of Inflammatory Disorders of the CNS at the Max Planck Institute of Psychiatry, Munich 80804, Germany4 Department of Neurosurgery, University of Erlangen, Erlangen 91054, Germany5 Affectis Pharmaceuticals, Munich 82152, Germany6 Laboratorio de Fisiología y Biología Molecular, University of Buenos Aires and CONICET, Buenos Aires 1428, Argentina
(Correspondence should be addressed to M Labeur; Email: labeur{at}mpipsykl.mpg.de)
Interferon-
(IFNG) is a cytokine that exerts potent antiproliferative and tumoricidal effects in a variety of cancers. Moreover, IFNG modulates normal pituitary hormone secretion, and was shown to inhibit the expression of the ACTH precursor POMC in murine ACTH-secreting AtT-2010/21/2008 tumor cells. We have studied the functional role of IFNG on pituitary tumor cells, focusing on the involvement of IFNG in the molecular events leading to the control of POMC transcriptional repression. Herein, it is shown that IFNG inhibits AtT-20 tumor cell proliferation without inducing apoptosis. Unexpectedly, an activated janus kinases–signal transducer and activator of transcription (JAK–STAT1) cascade is required for IFNG inhibitory action on POMC promoter activity. Factor-kappa B (NF-
B) is necessary for the inhibitory action of IFNG on Pomc transcription, since loss of NF-
B activity with I
B super-repressor abolishes this effect. In addition, 1 and 2 IFNG receptor immunoreactivity was detected in human corticotropinoma cells. Interestingly, IFNG inhibits ACTH production from these cells in primary cell culture, without affecting basal ACTH biosynthesis in normal non-tumoral pituitary cells. In conclusion, our data show for the first time that POMC transcription can be negatively regulated by a JAK–STAT1 and NF-
B-dependent pathway.
This article has been cited by other articles:
![]() |
A. J. Vangsted, T. W. Klausen, P. Gimsing, N. F. Andersen, N. Abildgaard, H. Gregersen, and U. Vogel A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support Haematologica, September 1, 2009; 94(9): 1274 - 1281. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |